| Paper | Authors | Journal | Year | Type |
|---|
| Single-center experience with Romiplostim N01 for the management of severe persistent cancer therapy-induced thrombocytopenia in lung cancer: Insights and outcomes | Wang C et al. | Medicine | 2026 | Observational Study |
| Hematopoietic Recovery and Safety Following Early Romiplostim Administration After Pediatric HSCT: A Prospective Randomized Pilot Study | Sarangarajan S et al. | Pediatric blood & cancer | 2026 | Randomized Controlled Trial |
| Evaluation of Safety and Efficacy of Romiplostim in the Treatment of Pediatric Immune Thrombocytopenia: A Real-World Observational Study | Attia SA et al. | Journal of pediatric hematology/oncology | 2026 | Observational Study |
| Switching patients with immune thrombocytopenia (ITP) to avatrombopag from other thrombopoietin receptor agonists: The real-world experience of the Spanish ITP Group (GEPTI) | Pascual-Izquierdo C et al. | British journal of haematology | 2026 | Observational Study |
| Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia | Al-Samkari H et al. | The New England journal of medicine | 2026 | Randomized Controlled Trial |
| Efficacy and Safety of Romiplostim in Treating Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Single-Arm Clinical Trial | Karimizadeh Z et al. | Transplantation and cellular therapy | 2026 | Clinical Trial |
| Combining an immunomodulatory drug with a TPO-RA to treat multirefractory ITP patients: The Spanish ITP Group experience | Mingot-Castellano ME et al. | British journal of haematology | 2026 | Observational Study |
| Evaluation of the efficacy and safety of initial high-dose romiplostim for primary immune thrombocytopenia in the acute care setting | Bringhurst G et al. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis | 2026 | Observational Study |
| Romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed immune thrombocytopenia: A pilot study | Colunga-Pedraza PR et al. | British journal of haematology | 2026 | Clinical Trial |
| Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study | Lee JW et al. | British journal of haematology | 2025 | Clinical Trial, Phase III |
| Romiplostim versus Recombinant human thrombopoietin in umbilical cord blood transplantation: a single-center retrospective study | Ding Y et al. | Annals of hematology | 2025 | Randomized Controlled Trial |
| Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials | Jang JH et al. | Annals of hematology | 2025 | Clinical Trial, Phase III |
| The 'Stop TPO-RA in ITP Patients' study: Clinical and immune modulatory effects of romiplostim tapering | Nelson VS et al. | British journal of haematology | 2025 | Clinical Trial |
| Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA | Tarantino MD et al. | Blood advances | 2025 | Clinical Trial, Phase IV |
| Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings | Obara N et al. | International journal of hematology | 2024 | Observational Study |
| Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome | Sharathkumar A et al. | Journal of pediatric hematology/oncology | 2024 | Observational Study |
| Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study | Cooper N et al. | British journal of haematology | 2024 | Observational Study |
| Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study | Mitani K et al. | Blood advances | 2024 | Clinical Trial, Phase III |
| A randomized, double-blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers | Makarenko I et al. | Pharmacology research & perspectives | 2023 | Randomized Controlled Trial |
| Transient increase in platelet counts associated with COVID-19 infection during TPO-RA as the second-line treatment in children with ITP | Wang Z et al. | British journal of haematology | 2023 | Observational Study |
| Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial | Kurita N et al. | Annals of hematology | 2023 | Clinical Trial, Phase I |
| Efficacy and safety of biosimilar romiplostim in Indian patients with chronic immune thrombocytopenia: A multicentric retrospective study | Iqbal A et al. | Indian journal of pathology & microbiology | 2023 | Observational Study |
| A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia | Grainger J et al. | Blood advances | 2023 | Clinical Trial, Phase III |
| Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible? | Solsona M et al. | British journal of clinical pharmacology | 2022 | Observational Study |
| Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study | Al-Samkari H et al. | British journal of haematology | 2022 | Observational Study |
| Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany | Reiser M et al. | Acta haematologica | 2022 | Observational Study |
| Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial | Qi J et al. | Clinical pharmacology in drug development | 2022 | Clinical Trial, Phase II |
| Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study | Skopec B et al. | Hematology (Amsterdam, Netherlands) | 2021 | Observational Study |
| Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia | Palandri F et al. | Blood | 2021 | Observational Study |
| Phase I Dose-Finding, Safety, and Tolerability Trial of Romiplostim to Improve Platelet Recovery After UCB Transplantation | Christakopoulos GE et al. | Transplantation and cellular therapy | 2021 | Clinical Trial, Phase I |